Antimicrobial Peptides Market: By Product (Animal Antimicrobial Peptides, Plant Antimicrobial Peptides, Bacterial Antimicrobial Peptides, Insect Antimicrobial Peptides), By Ailments (Hepatitis, Bacterial infections, HIV, Pneumonia), By Distribution Channel (Hospitals, Specialty Clinics, Research Institute, Pharmacies), by Route of Administration (Subcutaneous, Topical, Intravenous), By End User (Pharmaceuticals, Healthcare, Biological Engineering, Agriculture) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Antimicrobial Peptides Market is poised to grow at a significant CAGR of 5.80% from 2023-2029. The soaring drug-resistant infections have projected a serious challenge to the antimicrobial therapies. The Centers for Disease Control reports that each year in the United States, at least 2 million people become infected with bacteria that are resistant to antibiotics. At least 23,000 people die each year as a direct result of these infections. Antimicrobial peptides (AMPs) are also known as host defense peptides. They are short and usually positively charged peptides found in various life forms. The antimicrobial peptides have the ability to kill microbial pathogens directly. They are considered as the potential therapeutic sources of future antibiotics. Owing to their broad-spectrum activities and different mechanism of action when compared with that of conventional antibiotics. Antimicrobial peptides have constituted some major components of the innate immunity, protecting the host against infections.

 Antimicrobial Peptides Market Key Developments:
  • In February 2017, Symcel has partnered with Colzyx to test 25 new collagen VI-derived antimicrobial peptides in order to analyze their capability to halt bacterial growth.
    • The collagen VI-derived peptides test is performed using Symcel's CalScreener. The Symcel technology is flexible to test each peptide independently or in combination with others.
  • As per the research conducted by Anne Kokel et al recent strategies were reported for improving AMPs in the context of drug design and delivery were surveyed, and also their possible impact on patients and the environment was assessed
    • In the research, it is found that AMPs are considered to lack selectivity leading to side effects and cytotoxicity, and also exhibit in vivo instability. Several strategies are being actively considered to overcome the limitations that restrain the success of AMPs.
    • According to his analysis, the major advantage with AMPs is, it is the easily tunable skeleton that offers opportunities to improve their properties. Strategic structural modifications and the beneficial properties of cyclic or branched AMPs in term of stability have been reported. The conjugation of AMPs with nanoparticles has also been explored to increase their in vivo stability
    • The techniques such as the coupling of AMPs with specific antibodies aim to increase the selectivity of the potential drug towards the target. These strategies were evaluated for their effect on the environment highlighting green technologies
    • The report has been concluded saying that further research is needed taking into account both environmental and human health consequences of novel AMPs several of these compounds are promising drug candidates for use in sustainable medicine
  • University of Pittsburgh Innovation Institute – has conducted a research on the A4-antimicrobial peptides (A4-AMPs)
    • As per the research, A4-antimicrobial peptides (A4-AMPs) are a new class of peptide-based antibiotic that kills more than 90% of antibiotic-resistant species of bacteria. The study also says that A4 has a novel mechanism-of-action that does not confer resistance easily.
    • In the screening experiments in vitro have validated the excellent safety profile, the low propensity for drug resistance, and the strong antimicrobial activity of A4-AMPs against various superbugs
    • A provisional patent application was filed in 2016 over the A4 - A NOVEL PEPTIDE ANTIBIOTIC by the University of Pittsburgh Innovation Institute.
  • As per the study conducted by Abdurraouf Zaet et al over D-Cateslytin, a new antimicrobial peptide
    • D- Cateslytin has emerged as a potent, safe and robust peptide antimicrobial with undetectable susceptibility to resistance
    • Using Escherichia coli as the model in the study, it was observed that D-Ctl targets the bacterial cell wall leading to the permeabilization of the membrane and the death of the bacteria
      • The results obtained by the study has shown that:
      • D-Ctl is an efficient antimicrobial agent against various bacterial strains
      • D-Ctl is a potentiator for numerous antimicrobials
      • Unlike ampicillin and cefotaxime, D-Ctl does not trigger resistance in E. coli
      • D-Ctl is not cytotoxic and does not elicit cytokine release
      • D-Ctl is more resistant to degradation by secreted bacterial proteases than L-Ctl
      • D-Ctl dramatically damaged the cell wall of E. coli MDR
 

Antimicrobial Peptides Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.8%

Largest Market

North America

Fastest Growing Market

North America

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Antimicrobial Peptides Market Segmentation

By Product
  • Animal Antimicrobial Peptides
  • Plant Antimicrobial Peptides
  • Bacterial Antimicrobial Peptides
  • Insect Antimicrobial Peptides
By Ailments
  • Hepatitis
  • Bacterial infections
  • HIV
  • Pneumonia
By Distribution Channel
  • Hospitals
  • Specialty Clinics
  • Research Institute
  • Pharmacies
By Route of Administration
  • Subcutaneous
  • Topical
  • Intravenous
By End User
  • Pharmaceuticals
  • Healthcare
  • Biological Engineering
  • Agriculture

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

1.Executive Summary
2.Global Antimicrobial Peptides Market Introduction 
2.1.Global Antimicrobial Peptides Market  - Taxonomy
2.2.Global Antimicrobial Peptides Market  - Definitions
2.2.1.Product
2.2.2.Ailments
2.2.3.Distribution Channel
2.2.4.Route of Administration
2.2.5.Region
3.Global Antimicrobial Peptides Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Antimicrobial Peptides Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Antimicrobial Peptides Market  By Product, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Animal Antimicrobial Peptides
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Plant Antimicrobial Peptides
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Bacterial Antimicrobial Peptides
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Insect Antimicrobial Peptides
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Antimicrobial Peptides Market  By Ailments, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Hepatitis
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Bacterial infections
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. HIV
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Pneumonia
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7.Global Antimicrobial Peptides Market  By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospitals
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Specialty Clinics
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Research Institute
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Pharmacies
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8.Global Antimicrobial Peptides Market  By Route of Administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Subcutaneous
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Topical
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Intravenous
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9.Global Antimicrobial Peptides Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Antimicrobial Peptides Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Product Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Animal Antimicrobial Peptides
10.1.2.Plant Antimicrobial Peptides
10.1.3.Bacterial Antimicrobial Peptides
10.1.4.Insect Antimicrobial Peptides
10.2.  Ailments Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Hepatitis
10.2.2.Bacterial infections
10.2.3.HIV
10.2.4.Pneumonia
10.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospitals
10.3.2.Specialty Clinics
10.3.3.Research Institute
10.3.4.Pharmacies
10.4.  Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Subcutaneous
10.4.2.Topical
10.4.3.Intravenous
10.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Antimicrobial Peptides Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Product Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Animal Antimicrobial Peptides
11.1.2.Plant Antimicrobial Peptides
11.1.3.Bacterial Antimicrobial Peptides
11.1.4.Insect Antimicrobial Peptides
11.2.  Ailments Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Hepatitis
11.2.2.Bacterial infections
11.2.3.HIV
11.2.4.Pneumonia
11.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospitals
11.3.2.Specialty Clinics
11.3.3.Research Institute
11.3.4.Pharmacies
11.4.  Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Subcutaneous
11.4.2.Topical
11.4.3.Intravenous
11.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
11.5.6.Rest of EU
11.5.7.
12.Asia Pacific (APAC) Antimicrobial Peptides Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Product Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Animal Antimicrobial Peptides
12.1.2.Plant Antimicrobial Peptides
12.1.3.Bacterial Antimicrobial Peptides
12.1.4.Insect Antimicrobial Peptides
12.2.  Ailments Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Hepatitis
12.2.2.Bacterial infections
12.2.3.HIV
12.2.4.Pneumonia
12.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospitals
12.3.2.Specialty Clinics
12.3.3.Research Institute
12.3.4.Pharmacies
12.4.  Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Subcutaneous
12.4.2.Topical
12.4.3.Intravenous
12.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Antimicrobial Peptides Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Product Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Animal Antimicrobial Peptides
13.1.2.Plant Antimicrobial Peptides
13.1.3.Bacterial Antimicrobial Peptides
13.1.4.Insect Antimicrobial Peptides
13.2.  Ailments Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Hepatitis
13.2.2.Bacterial infections
13.2.3.HIV
13.2.4.Pneumonia
13.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospitals
13.3.2.Specialty Clinics
13.3.3.Research Institute
13.3.4.Pharmacies
13.4.  Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Subcutaneous
13.4.2.Topical
13.4.3.Intravenous
13.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Antimicrobial Peptides Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
14.1. Product Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Animal Antimicrobial Peptides
14.1.2.Plant Antimicrobial Peptides
14.1.3.Bacterial Antimicrobial Peptides
14.1.4.Insect Antimicrobial Peptides
14.2.  Ailments Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Hepatitis
14.2.2.Bacterial infections
14.2.3.HIV
14.2.4.Pneumonia
14.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Hospitals
14.3.2.Specialty Clinics
14.3.3.Research Institute
14.3.4.Pharmacies
14.4.  Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Subcutaneous
14.4.2.Topical
14.4.3.Intravenous
14.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Eli Lilly and Company
15.2.2.Pfizer Inc.
15.2.3.GSK Group of Companies
15.2.4.Novartis AG
15.2.5.EnBiotix Inc.
15.2.6.Johnson & Johnson Private Limited
15.2.7.Merck & Co., Inc.
15.2.8.Alexion Pharmaceuticals, Inc.
15.2.9.Melinta Therapeutics, LLC
15.2.10.Vertex Pharmaceuticals Incorporated
15.2.11.AnaSpec
15.2.12.AMP Biotech
16. Research Methodology 
17. Appendix and Abbreviations 
  • Eli Lilly and Company
  • Pfizer Inc.
  • GSK Group of Companies
  • Novartis AG
  • EnBiotix Inc.
  • Johnson & Johnson Private Limited
  • Merck & Co., Inc.
  • Alexion Pharmaceuticals, Inc.
  • Melinta Therapeutics, LLC
  • Vertex Pharmaceuticals Incorporated
  • AnaSpec
  • AMP Biotech

Adjacent Markets